subunit vaccines

Summary

Summary: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.

Top Publications

  1. ncbi The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis
    Min Li
    The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, People s Republic of China
    DNA Cell Biol 27:405-13. 2008
  2. pmc VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines
    Irini A Doytchinova
    Faculty of Pharmacy, Medical University of Sofia, 2 Dunav St, 1000 Sofia, Bulgaria
    BMC Bioinformatics 8:4. 2007
  3. ncbi Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
    Thomas Bennekov
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Eur J Immunol 36:3346-55. 2006
  4. ncbi Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine
    V Yusibov
    Biotechnology Foundation Laboratories at Thomas Jefferson University, 1020 Locust Street, Room 346 JAH, Philadelphia, PA 19107, USA
    Vaccine 20:3155-64. 2002
  5. ncbi More than one reason to rethink the use of peptides in vaccine design
    Anthony W Purcell
    The Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Victoria 3010, Australia
    Nat Rev Drug Discov 6:404-14. 2007
  6. ncbi Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
    Michelle Nelson
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 53:1177-82. 2004
  7. ncbi Advances and prospects for subunit vaccines against protozoa of veterinary importance
    M C Jenkins
    Immunology and Disease Resistance Laboratory, Agricultural Research Service, US Department of Agriculture USDA, Beltsville, MA 20705, USA
    Vet Parasitol 101:291-310. 2001
  8. ncbi A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    Kimberly A Chianese-Bullock
    Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:420-30. 2008
  9. pmc Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production
    Ashlesh K Murthy
    Department of Biology, University of Texas at San Antonio, 6900N Loop 1604W, San Antonio, TX 78249, USA
    Infect Immun 75:666-76. 2007
  10. ncbi Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys
    Jiang Fan
    Department of Vaccine and Biologics Research, Merck Research Laboratories, 770 Sumneytown Pike, P O Box 4, WP16 306, West Point, PA 19486, USA
    Vaccine 22:2993-3003. 2004

Detail Information

Publications257 found, 100 shown here

  1. ncbi The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis
    Min Li
    The National Laboratory of Protein Engineering and Plant Genetic Engineering, Peking University, Beijing, People s Republic of China
    DNA Cell Biol 27:405-13. 2008
    ..Taken together, our results indicate that the synthetic peptide KLKL(5)KLK is a potent adjuvant that can enhance and prolong the immune response of the combined DNA vaccine against M. tuberculosis...
  2. pmc VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines
    Irini A Doytchinova
    Faculty of Pharmacy, Medical University of Sofia, 2 Dunav St, 1000 Sofia, Bulgaria
    BMC Bioinformatics 8:4. 2007
    ....
  3. ncbi Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis
    Thomas Bennekov
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Eur J Immunol 36:3346-55. 2006
    ....
  4. ncbi Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine
    V Yusibov
    Biotechnology Foundation Laboratories at Thomas Jefferson University, 1020 Locust Street, Room 346 JAH, Philadelphia, PA 19107, USA
    Vaccine 20:3155-64. 2002
    ..These findings provide clear indication of the potential of the plant virus-based expression systems as supplementary oral booster for rabies vaccinations...
  5. ncbi More than one reason to rethink the use of peptides in vaccine design
    Anthony W Purcell
    The Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Victoria 3010, Australia
    Nat Rev Drug Discov 6:404-14. 2007
    ..We discuss the potential of peptide-based vaccines for the treatment of chronic viral diseases and cancer, and review recent developments in the field of peptide-based vaccines...
  6. ncbi Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
    Michelle Nelson
    Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK
    J Med Microbiol 53:1177-82. 2004
    ..This study is the first time antigens protective by active immunization have been identified and suggests that polysaccharides have potential as vaccine candidates against melioidosis...
  7. ncbi Advances and prospects for subunit vaccines against protozoa of veterinary importance
    M C Jenkins
    Immunology and Disease Resistance Laboratory, Agricultural Research Service, US Department of Agriculture USDA, Beltsville, MA 20705, USA
    Vet Parasitol 101:291-310. 2001
    ..b>Subunit vaccines offer an attractive alternative to virulent or attenuated parasites for several reasons...
  8. ncbi A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer
    Kimberly A Chianese-Bullock
    Department of Surgery, Division of Surgical Oncology, Human Immune Therapy Center, University of Virginia, Charlottesville, VA 22908, USA
    J Immunother 31:420-30. 2008
    ....
  9. pmc Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production
    Ashlesh K Murthy
    Department of Biology, University of Texas at San Antonio, 6900N Loop 1604W, San Antonio, TX 78249, USA
    Infect Immun 75:666-76. 2007
    ..Together, these results demonstrate that secreted chlamydial antigens may be novel vaccine candidates to induce protective immunity...
  10. ncbi Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys
    Jiang Fan
    Department of Vaccine and Biologics Research, Merck Research Laboratories, 770 Sumneytown Pike, P O Box 4, WP16 306, West Point, PA 19486, USA
    Vaccine 22:2993-3003. 2004
    ..The data presented here will permit better understanding of the potential of an M2-based vaccine approach...
  11. pmc Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis
    Nicholas O Fischer
    Lawrence Livermore National Laboratory, Livermore, California 94551, USA
    Bioconjug Chem 21:1018-22. 2010
    ....
  12. ncbi Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge
    S M de Boer
    Central Veterinary Institute of Wageningen University and Research Centre, Cluster of Mammalian Virology, Edelhertweg 15, 8219 PH, Lelystad, The Netherlands
    Vaccine 28:2330-9. 2010
    ..Importantly, absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocapsid protein-based indirect ELISA...
  13. ncbi Recombinant subunit vaccines: potentials and constraints
    T G Clark
    Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA
    Dev Biol (Basel) 121:153-63. 2005
    ..Less onerous from a regulatory standpoint, recombinant subunit vaccines generate strong antibody responses in recipient animals when administered parenterally with adjuvant-..
  14. ncbi Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites
    M Tsuji
    Department of Medical and Molecular Parasitology, New York University School of Medicine, 341 East 25th Street, New York, NY 10010, USA
    Mol Immunol 38:433-42. 2001
    ..Therefore, the development of peptide-based subunit vaccines has been undertaken as an alternative approach...
  15. pmc Assessment of the genetic diversity of Mycobacterium tuberculosis esxA, esxH, and fbpB genes among clinical isolates and its implication for the future immunization by new tuberculosis subunit vaccines Ag85B-ESAT-6 and Ag85B-TB10.4
    Jose Davila
    Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI 48109 2029, USA
    J Biomed Biotechnol 2010:208371. 2010
    ..than the widely used Bacille Calmette-Guérin (BCG) has led to the development of two novel fusion protein subunit vaccines: Ag85B-ESAT-6 and Ag85B-TB10.4...
  16. ncbi Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers
    Naotake Tsuda
    Departments of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Fukuoka, Japan
    J Immunother 27:60-72. 2004
    ....
  17. ncbi Recombinant attenuated bacteria for the delivery of subunit vaccines
    I Gentschev
    Department of Microbiology, University of Wuerzburg, D-97074, Wuerzburg, Germany
    Vaccine 19:2621-8. 2001
    ..attenuated intracellular bacteria as carriers, we have developed two different approaches for the delivery of subunit vaccines encoding heterologous antigens...
  18. pmc Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines; immunity, pathology and protection
    Else Marie Agger
    Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
    Immunology 124:175-85. 2008
    ..We designed a panel of Ag85B-ESAT-6 subunit vaccines based on adjuvants with different Th1/Th2-promoting activities and studied cellular responses, bacterial ..
  19. ncbi Lipopeptide vaccines--yesterday, today, and tomorrow
    Lbachir BenMohamed
    Ophthalmology Research Laboratories, Burns and Allen Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Lancet Infect Dis 2:425-31. 2002
    ..In particular, the recent development of mucosal application of lipopeptide vaccines may present an ideal strategy against many pathogens that infect mucosal surfaces...
  20. ncbi Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade
    Eduardo Davila
    Department of Immunology, Mayo Clinic and Mayo Graduate School, Rochester, Minnesota 55905, USA
    Cancer Res 63:3281-8. 2003
    ..These findings bear clinical significance for the design of peptide-based therapeutic vaccines for human cancer patients...
  21. ncbi Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines
    Shu Wen W Chen
    Ecole Superieure de Biotechnologie de Strasbourg, CNRS, F 67412 Illkirch, France
    Curr Med Chem 16:953-64. 2009
    ....
  22. ncbi Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy
    Jes Dietrich
    Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark
    J Immunol 174:6332-9. 2005
    ..4, we show that ESAT-6, apart from being an excellent diagnostic reagent, can also be used as a reagent for monitoring vaccine efficacy. This may open a new way for monitoring vaccine efficacy in clinical trials...
  23. ncbi Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model
    Lanying Du
    State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
    Vaccine 25:2832-8. 2007
    ..In conclusion, our findings suggest that RBD, which can induce protective antibodies to SARS-CoV, may be further developed as a safe and effective SARS subunit vaccine...
  24. ncbi Inactivated and subunit vaccines to prevent shigellosis
    Robert W Kaminski
    Division of Bacterial and Rickettsial Diseases, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    Expert Rev Vaccines 8:1693-704. 2009
    ..Outlined here is an overview of multiple nonliving vaccine technologies, highlighting their current status and recent advances in testing. In addition, gaps in the knowledge base regarding immune mechanisms of protection are explored...
  25. pmc DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy
    Andrea M Hebert
    Epidemiology Department, School of Public Health, University of Michigan, 109 S Observatory Street, Ann Arbor, MI 48109 2029, USA
    Infect Immun 75:5798-805. 2007
    ..Thus, immunity induced by Mtb72F may not recognize a proportion of M. tuberculosis clinical strains...
  26. ncbi Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease
    Colleen Olive
    The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Curr Opin Mol Ther 9:25-34. 2007
    ..The development of subunit vaccine approaches targeting the M protein using various vaccine delivery technologies is the focus of this review...
  27. ncbi Human immune recognition-based multicomponent subunit vaccines against tuberculosis
    S B Sable
    Dept of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India
    Eur Respir J 25:902-10. 2005
    ..The aim of this study was to evaluate the protective potential of two multicomponent subunit vaccines (MSV-1 and MSV-2) against tuberculosis (TB) based on human immune recognition...
  28. ncbi Evaluation of ISCOM-adjuvanted subunit vaccines containing recombinant feline immunodeficiency virus Rev, OrfA and envelope protein in cats
    Willem Huisman
    Erasmus MC, Institute of Virology, Rotterdam, The Netherlands
    Vaccine 26:2553-61. 2008
    ..In the present study, subunit vaccines containing recombinant FIV accessory proteins Rev and OrfA were evaluated in cats...
  29. pmc Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA
    Morten A Nielsen
    Department of International Health, Immunology, and Microbiology, University of Copenhagen, Department of Infectious Diseases, Copenhagen University Hospital, Copenhagen, Denmark
    Infect Immun 77:2482-7. 2009
    ..As the inhibition was not limited to homologous parasite strains, it seems feasible to base a protective malaria vaccine on a single VAR2CSA DBL domain...
  30. ncbi Construction and evaluation of a multistage combination vaccine against malaria
    Qingfeng Zhang
    Department of Etiologic Biology and State Key Laboratory of Medical Immunology, Second Military Medical University, 800 Xiang Yin Road, Shanghai 200433, China
    Vaccine 25:2112-9. 2007
    ..Rabbits antisera to combination antigens strongly inhibited blood-stage parasite growth in vitro. These results suggest that the recombinant antigens are potential candidates for multistage combination vaccines against malarial parasite...
  31. ncbi Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults
    Michel Moutschen
    Department of Infectious Diseases and General Internal Medicine, CHU Sart Tilman, University of Liege, Liege, Belgium
    Vaccine 25:4697-705. 2007
    ..The gp350 vaccine formulations were immunogenic and induced gp350-specific antibody responses (including neutralising antibodies)...
  32. pmc Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines
    L Holten-Andersen
    Department of Infectious Disease Immunology, Statens Serum Institut, DK 2300 Copenhagen, Denmark
    Infect Immun 72:1608-17. 2004
    ..tuberculosis infection in a vaccination model and thus appears to be a very promising candidate for the development of human vaccines...
  33. ncbi Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting
    Craig L Slingluff
    Department of Surgery, University of Virginia, Charlottesville, Virginia 22908, USA
    Clin Cancer Res 13:6386-95. 2007
    ..Because melanomas commonly evade immune recognition by selective antigen loss, optimization of melanoma vaccines may require development of more complex multipeptide vaccines...
  34. ncbi Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3
    Robert P Webb
    United States Army Medical Research Institute for Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, United States
    Vaccine 27:4490-7. 2009
    ..Differences in protective immunity diminished after multiple vaccinations with either ciBoNT/A1 HP or BoNT/A1 H(c), and the survival rates were more comparable at the toxin levels used to challenge...
  35. ncbi Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6
    Jan A M Langermans
    Department of Parasitology, Biomedical Primate Research Centre, P O Box 3306, 2280 GH Rijswijk, The Netherlands
    Vaccine 23:2740-50. 2005
    Various new tuberculosis (TB) vaccine candidates in combination with new delivery systems, including subunit vaccines, are currently being evaluated by a number of laboratories...
  36. pmc Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen
    Regine Audran
    Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, BH 19, Rue du Bugnon, 1011 Lausanne, Switzerland
    Infect Immun 73:8017-26. 2005
    ..e., the type of anti-MSP3 antibodies involved in antibody-dependent, monocyte-mediated protective mechanisms in areas where malaria is endemic)...
  37. ncbi Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41
    Christoph S Klade
    Intercell AG, Vienna, Austria
    Gastroenterology 134:1385-95. 2008
    ..We aimed to investigate whether IC41 is able to induce HCV-specific T-cell responses also in chronic hepatitis C patients...
  38. ncbi Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials
    Helen McShane
    Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Tuberculosis (Edinb) 85:47-52. 2005
    ..MVA85A is now in clinical trials in the UK and Africa and the design of these trials, including the ethical and regulatory issues are discussed...
  39. pmc Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H-
    P M van Diemen
    Institute for Animal Health, Compton, Berkshire RG20 7NN, UK
    Vet Immunol Immunopathol 116:47-58. 2007
    ..roles in intestinal colonisation of cattle by EHEC and are thus attractive candidates for the development of subunit vaccines. Immunisation of calves with the cell-binding domain of intimin subtypes beta or gamma via the intramuscular ..
  40. pmc High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
    Sandra Hervas-Stubbs
    Biologie des Régulations Immunitaires, INSERM, E 352, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
    Infect Immun 74:3396-407. 2006
    ..4 protein as a candidate vaccine and show that the presence of high frequencies of CD4+ T cells specific to this strong immunogen correlates with protection against M. tuberculosis infection...
  41. ncbi A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice
    Anil Vangala
    Medicines Research Unit, School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK
    J Pharm Pharmacol 58:787-99. 2006
    ..The MP- and DDA-based systems induced antibody responses at comparable levels whereas the DDA-based systems induced more powerful cell-mediated immune responses...
  42. ncbi New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine
    Hanne Gahery
    Institut Cochin, Departement d Immunologie, INSERM U567, CNRS UMR8104, Universite Rene Descartes, 75014 Paris, France
    AIDS Res Hum Retroviruses 22:684-94. 2006
    ..Lipopeptides induce new anti-HIV T cell responses in vaccinated infected patients and could be used as a new immunotherapy strategy. The majority of these responders induced specific new CD4(+) and CD8(+) T cell responses...
  43. ncbi Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines
    E A Simoes
    Department of Pediatrics, Section of Infectious Diseases, Health Sciences Center, University of Colorado, Denver, CO, USA
    Vaccine 20:954-60. 2001
    ..The effect of vaccination on RSV LRI did not reach statistical significance. CONCLUSIONS: RSV subunit vaccines were found to reduce the overall incidence of all RSV infections...
  44. ncbi Synthetic peptide vaccine against Taenia solium pig cysticercosis: successful vaccination in a controlled field trial in rural Mexico
    M Huerta
    Facultad de Medicina, , Puebla, Mexico
    Vaccine 20:262-6. 2001
    ....
  45. ncbi Further evaluation of the synthetic peptide vaccine S3Pvac against Taenia solium cysticercosis in pigs in an endemic town of Mexico
    E Sciutto
    Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, AP 70228, Ciudad Universitaria, 04510 Mexico, DF Mexico
    Parasitology 134:129-33. 2007
    ..Thus, this investigation shows the limited usefulness of single vaccination as the sole means of interrupting Taenia solium transmission in an endemic region...
  46. ncbi Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome
    Tal Vider-Shalit
    Math Department, Bar Ilan University, 52900 Ramat Gan, Israel
    Mol Immunol 44:1253-61. 2007
    ..In order to show the applicability of our method, we have further used it on HIV-I, Influenza H3N2 and the Avian Flu Viruses...
  47. pmc Expression of HIV-1 antigens in plants as potential subunit vaccines
    Ann Meyers
    Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa
    BMC Biotechnol 8:53. 2008
    ..We partially purified a selected vaccine candidate and tested its stimulation of a humoral and cellular immune response in mice...
  48. ncbi Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties
    Irini A Doytchinova
    Faculty of Pharmacy, Medical University of Sofia, Dunav st 2, 1000 Sofia, Bulgaria
    Vaccine 25:856-66. 2007
    ..The prediction accuracy is 83% for the cross-validation and 80% for the external test set. Our approach is accurate and robust, and provides a potent tool for the in silico discovery of medically relevant subunit vaccines.
  49. ncbi "Self-nonself" peptides in the design of vaccines
    Darja Kanduc
    Department of Biochemistry and Molecular Biology, University of Bari, 70126 Bari, Italy
    Curr Pharm Des 15:3283-9. 2009
    ..Biologically, the low-similarity hypothesis further supports sequence uniqueness as the molecular signature of "nonselfness" in the currently ongoing self/non-self debate...
  50. ncbi A novel strategy for protective Actinobacillus pleuropneumoniae subunit vaccines: detergent extraction of cultures induced by iron restriction
    R Goethe
    Institut für Mikrobiologie und Tierseuchen, Tieraerztliche Hochschule Hannover, Bischofsholer Damm 15, 30173, Hannover, Germany
    Vaccine 19:966-75. 2000
    ..pleuropneumoniae serotype 2, the immunized pigs showed no or only mild clinical signs of disease and had a significantly lower degree of lung damage than the control pigs...
  51. pmc Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists
    Matthew Black
    University of California, Santa Barbara, CA 93106, USA
    Expert Rev Vaccines 9:157-73. 2010
    ..A survey of recent approaches to developing peptide antigen delivery systems is given, many of which incorporate Toll-like receptor agonists into the design...
  52. pmc Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
    P Durando
    Department of Health Sciences, University of Genoa, 16132 Genoa, Italy
    Clin Vaccine Immunol 15:253-9. 2008
    ..both the safety and tolerability and the humoral and cell-mediated immune responses for two influenza virus subunit vaccines, one with MF59 adjuvant (Fluad) and one without an adjuvant (Agrippal), in healthy and in human ..
  53. ncbi Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice
    Ruihong Zeng
    Department of Immunology, Hebei Medical University, Zhongshan East Road 361, Shijiazhuang, Hebei Province 050017, China
    Biochem Biophys Res Commun 377:495-9. 2008
    ..We have engineered a subunit vaccine candidate G1F/M2. A major problem in developing subunit vaccines is their limited immunogenicity...
  54. ncbi Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines
    J N Wilson
    Department of Biological Sciences, University of Warwick, Coventry, United Kingdom
    J Med Virol 64:560-8. 2001
    ..In this paper two principal questions are identified which need to be addressed in the evaluation of subunit vaccines: i) how do specific antibody levels relate to complete protection from infection or disease and ii) how do ..
  55. ncbi Development of subunit vaccines against severe acute respiratory syndrome
    Lanying Du
    Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
    Drugs Today (Barc) 44:63-73. 2008
    ..After comparing current vaccine categories against SARS, this article will demonstrate the advantages of subunit vaccines, describe the current situation of developing subunit vaccines, and point out the possibility for further ..
  56. ncbi Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors
    Petra Walcher
    Institute of Microbiology and Genetics, Department Microbiology and Biotechnology, University of Vienna, UZA II, 2B255, Althanstrasse 14, A 1090 Wien, Austria
    Expert Rev Vaccines 3:681-91. 2004
    ..The main advantages of BGs as carriers of subunit vaccines include their ability to stimulate a high immune response and to target the carrier itself to primary antigen-..
  57. ncbi Plants as biofactories for the production of subunit vaccines against bio-security-related bacteria and viruses
    M Manuela Rigano
    Department of Soil, Plant, Environmental and Animal Production Sciences, University of Naples, Via Universita 100, 80055 Portici, Italy
    Vaccine 27:3463-6. 2009
    ..These data demonstrated that the plant-based approach is feasible for manufacturing recombinant vaccines against bio-terror agents that could be mass-produced at reasonable cost...
  58. ncbi Protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice
    Hui Gang Shen
    Laboratory of Virology and Immunology, Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310029, PR China
    J Gen Virol 89:1857-65. 2008
    ..An open reading frame 2 plasmid (pORF2) and the capsid protein (Cap) of PCV2 were used as DNA and subunit vaccines, respectively...
  59. ncbi Pitfalls of reductionism in the design of peptide-based vaccines
    M H Van Regenmortel
    Laboratoire d'Immunochimie des Virus et des Peptides, Institut de Biologie Moleculaire et Cellulaire du CNRS, UPR 9021, , 67084 Cedex, Strasbourg, France
    Vaccine 19:2369-74. 2001
    ..A reductionist approach does not provide the information required for designing peptide immunogens that will elicit neutralizing rather than non-neutralizing antibody responses...
  60. ncbi Characterization of a polymorphic Theileria annulata surface protein (TaSP) closely related to PIM of Theileria parva: implications for use in diagnostic tests and subunit vaccines
    Leonhard Schnittger
    Forschungszentrum Borstel, Parkallee 22, 23845 Borstel, Germany
    Mol Biochem Parasitol 120:247-56. 2002
    ..The existence of the predicted secretion signal peptide and membrane spanning regions suggest that TaSP is located at the parasite membrane...
  61. ncbi Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system
    Anthony B Nesburn
    Laboratory of Cellular and Molecular Immunology, Department of Ophthalmology, University of California Irvine, Irvine, California 92868 4380, USA
    Ocul Surf 4:178-87. 2006
    ..The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed...
  62. ncbi Mucosal immunoadjuvant activity of the low toxic recombinant Escherichia coli heat-labile enterotoxin produced by Bacillus brevis for the bacterial subunit or component vaccine in pigs and cattle
    Y Yokomizo
    National Institute of Animal Health, Kannondai 3 1 5, Ibarakiken, Japan
    Vet Immunol Immunopathol 87:291-300. 2002
    ..brevis expression system might represent promising immunoadjuvants for the potential application of intranasal vaccines directed against infectious diseases in pigs and cattle...
  63. ncbi TB subunit vaccines--putting the pieces together
    Peter Andersen
    Department of Infectious Disease Immunology, Statens Serum Institut, 5 Artillerivej, 2300 Copenhagen, Denmark
    Microbes Infect 7:911-21. 2005
    ..This requires carefully monitoring aspects as immunodominance, recognition in different populations as well as vaccine manufacturing...
  64. ncbi Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum
    Sima Rafati
    Molecular Immunology Lab, Department of Immunology, Pasteur Institute of Iran, P O Box 11365 6699, Tehran, Iran
    Vaccine 23:3716-25. 2005
    ..We propose that the combination of DNA and recombinant protein vaccination using CPs could be instrumental to control (VL) in dogs...
  65. ncbi Tuberculosis subunit vaccines: from basic science to clinical testing
    T Mark Doherty
    Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark
    Expert Opin Biol Ther 7:1539-49. 2007
    ..The selection of antigens on which new subunit vaccines are based represent the first fulfillment of the promise of proteomics and genomics, and the delivery systems ..
  66. ncbi DNA versus protein immunisation for production of monoclonal antibodies against Choristoneura fumiferana ecdysone receptor (CfEcR)
    Dan Hui Yang
    Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    Vaccine 24:3115-26. 2006
    ....
  67. ncbi Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation
    C Olive
    Cooperative Research Centre for Vaccine Technology, Division of Infectious Diseases and Immunology, The Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia
    Vaccine 25:1789-97. 2007
    ..This is the first report demonstrating the elicitation of better protective immunity by a dual antigen component S. pyogenes vaccine...
  68. ncbi Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection
    Kelly L Warfield
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA
    J Immunol 175:1184-91. 2005
    ..Taken together, both EBOV-specific humoral and cytotoxic CD8(+) T cell responses are critical to mediate protection against filoviruses following eVLP vaccination...
  69. pmc Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge
    Anna U Bielinska
    Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, 1150 West Medical Center Drive, Ann Arbor, MI 48109 0648, USA
    Infect Immun 75:4020-9. 2007
    ..This potentially could lead to a needle-free anthrax vaccine requiring fewer doses and having fewer side effects than the currently available human vaccine...
  70. pmc Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A
    Clara Brando
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, USA
    Infect Immun 75:838-45. 2007
    ....
  71. pmc Streptococcus pneumoniae pilus subunits protect mice against lethal challenge
    Claudia Gianfaldoni
    Novartis Vaccines and Diagnostics s r l, Research Center, Via Fiorentina 1, I 53100 Siena, Italy
    Infect Immun 75:1059-62. 2007
    ..Both active and passive immunization with recombinant pilus subunits afforded protection against lethal challenge with the S. pneumoniae serotype 4 strain TIGR4...
  72. ncbi Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines
    Jun Miao
    Department of Entomology, The Pennsylvania State University, 501 ASI Building, University Park, PA 16802, USA
    Vaccine 24:6187-98. 2006
    ..This study has yielded useful information for further in vivo evaluation of the suitability and effectiveness of the heterologous prime-boost strategy in AMA1 vaccination...
  73. pmc Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis
    David N Harland
    Department of Molecular Microbiology, School of Biosciences, Geoffrey Pope Building, University of Exeter, Exeter, United Kingdom
    Infect Immun 75:4173-80. 2007
    ..Immunization with LolC also protected against a subsequent challenge with a heterologous strain of B. pseudomallei, demonstrating the potential utility of this protein as a vaccine antigen for melioidosis...
  74. ncbi Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen
    Pavlo Sakhatskyy
    Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Rm 304, LRB, 364 Plantation Street, Worcester, MA 01605, USA
    Virology 355:164-74. 2006
    ..Therefore, D8 is an excellent candidate antigen to be included in the final polyvalent subunit-based poxvirus vaccines...
  75. ncbi DNA priming E and NS1 constructs--homologous proteins boosting immunization strategy to improve immune response against dengue in mice
    Gabriela Mellado-Sanchez
    Departamento de Biomedicina Molecular Centro de Investigación y Estudios Avanzadas del IPN, Mexico, DF Mexico
    Viral Immunol 18:709-21. 2005
    ..These results suggest that NS1 and E proteins together could be considered in a design of subunit recombinant vaccines...
  76. ncbi Nanodecoy system: a novel approach to design hepatitis B vaccine for immunopotentiation
    Amit K Goyal
    Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr Harisingh Gour Vishwavidyalaya, Sagar, MP 470003, India
    Int J Pharm 309:227-33. 2006
    The progress toward subunit vaccines has been limited by their poor immunogenicity and limited stability. To enhance the immune response, subunit vaccines universally require improved adjuvants and delivery vehicles...
  77. ncbi Jaagsiekte sheep retrovirus-specific immune responses induced by vaccination: a comparison of immunisation strategies
    Christina Summers
    Medical Microbiology, University of Edinburgh, Scotland, UK
    Vaccine 24:1821-9. 2006
    ..These results will help in the design of a protective vaccine against JSRV infection and the development of OPA...
  78. ncbi An hsp70 fusion protein vaccine potentiates the immune response against Japanese encephalitis virus
    F F Ge
    Key Laboratory of Animal Disease Diagnosis and Immunology, Ministry of Agriculture, Nanjing Agricultural University, Nanjing, PR China
    Arch Virol 152:125-35. 2007
    ..Immunization with the fusion protein generated both humoral and cellular immune responses to JEV, and the fusion protein appeared to be a more efficient protectant than the JEV SA14-14-2 vaccine...
  79. ncbi Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines
    Julien Taieb
    ERM 0208 Institut National de la Santé et de la Recherche Médicale, Faculté Kremlin Bicêtre, Institut Gustave Roussy, Villejuif, France
    J Immunol 176:2722-9. 2006
    ..Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells...
  80. ncbi Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice
    Stefan Wagner
    Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Breast Cancer Res Treat 106:29-38. 2007
    ..Our findings clearly demonstrate that this multi-peptide vaccine is effective in tumor prevention and support its use against minimal disease, drug-resistant tumors or even for prophylaxis against cancers overexpressing Her-2/neu...
  81. pmc Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines
    Yanmin Wan
    State Key Laboratory for Infectious Diseases Prevention and Control, National Center for AIDS STD Control and Prevention NCAIDS, China CDC, 27 Nanwei Road, Xuanwu District, Beijing 100050, China
    Vaccine 25:4949-59. 2007
    ..However, it remains to be determined that how these observations are relevant to the neutralization of antibody activities...
  82. ncbi Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
    Shih Jen Liu
    Vaccine Research and Development Center, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan ROC
    Vaccine 24:3100-8. 2006
    ..This information is very important for the development SARS diagnostic kits and a vaccine...
  83. ncbi Immune response induced by a different combined immunization of HBsAg vaccine
    Ting Wu
    National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China
    Intervirology 50:336-40. 2007
    ..To evaluate the immune responses induced by different combined immunizations of HBsAg protein vaccine (P), recombinant vaccinia virus vaccine (V) and DNA vaccine (D)...
  84. ncbi Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients
    Sima Rafati
    Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 25:4159-69. 2007
    ..This study demonstrates the potential of HSP70 in stimulating humoral responses in humans and mice and indicates there is a need to further explore and examine the value of this important molecule in the control of leishmaniasis...
  85. ncbi Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection
    Yasuko Asahi-Ozaki
    Department of Pathology, National Institute of Infectious Diseases, 4 7 1 Gakuen, Musashimurayama shi, Tokyo 208 0011, Japan
    Microbes Infect 8:2706-14. 2006
    ..These results indicate that poly (I:C) and CMP are highly effective as mucosal adjuvants for use with the nasal H5N1 vaccine...
  86. pmc Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain
    Emmie de Wit
    Department of Virology, Erasmus Medical Center, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    J Virol 79:12401-7. 2005
    ..The data presented suggest that vaccine candidates based on low-pathogenicity avian influenza A viruses, which can be prepared ahead of pandemic threats, can be efficacious if an effective adjuvant is used...
  87. ncbi Effectiveness of vaccination with recombinant HpaA from Helicobacter pylori is influenced by host genetic background
    Philip Sutton
    Centre for Animal Biotechnology, University of Melbourne, Melbourne, Victoria, Australia
    FEMS Immunol Med Microbiol 50:213-9. 2007
    ..HpaA therefore has potential for the development of effective immunization against H. pylori but this would probably entail the antigen to be one component of a multiantigenic vaccine...
  88. ncbi Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis
    M Raska
    Department of Immunology, Faculty of Medicine, Palacky University, Olomouc, Czechia
    Folia Microbiol (Praha) 50:77-82. 2005
    ..d. protein and DNA vaccination approaches. We stressed the importance of specific humoral immunity in the mouse model of systemic candidiasis...
  89. ncbi A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine
    N Dagouassat
    , Centre d'Immunologie Pierre-Fabre, , BP 497, F74164, Saint-Julien-en-Genevois, France
    Vaccine 19:4143-52. 2001
    ..From a physicochemical point of view, this unique property of BBG2Na makes it eminently suitable for combination to either paediatric or elderly multivalent AH- or AP-containing vaccines already in the market or in development...
  90. ncbi Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles
    Leenu Sabhnani
    Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India
    FEMS Immunol Med Microbiol 38:215-29. 2003
    ..Thus, the study highlights the importance of B and T cell epitopes as peptide-based immunogens, being a serious alternative for plague vaccine...
  91. ncbi HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice
    Yutaka Motomura
    Cancer Immunotherapy Project, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa 277 8577, Japan
    Int J Oncol 32:985-90. 2008
    ..The results of this study suggested that IFA is one of the indispensable adjuvants for peptide-based immunotherapy, and that the immunological effect of peptide vaccines depends on the dose of peptide injected...
  92. ncbi Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies
    Azam Bolhassani
    Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran
    Vaccine 26:3362-70. 2008
    ..Our study demonstrated that co-delivery of E7+Gp96 as DNA/DNA and E7+CT-gp96 as DNA/protein could be an effective approach to induce E7-specific immune responses as a potential vaccine candidate for cervical cancer...
  93. ncbi A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats
    Jennifer A McEachern
    CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
    Vaccine 26:3842-52. 2008
    ..The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses...
  94. ncbi The use of HLA class I tetramers to design a vaccination strategy for melanoma patients
    Michael Palmowski
    Weatherall Institute of Molecular Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Immunol Rev 188:155-63. 2002
    ..These results provide important pointers for future vaccination trials, and tetramers will form an important tool in the immunomonitoring of these clinical studies...
  95. ncbi Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen
    Pierre G Coulie
    Cellular Genetics Unit, Institute of Cellular Pathology, Universite de Louvain, Brussels, Belgium
    Immunol Rev 188:33-42. 2002
    ..In 4/9 regressor patients and in 1/14 progressors we found a low level, usually monoclonal cytolytic T lymphocyte response against the MAGE-3 peptide...
  96. ncbi Evaluation of immune response to recombinant potential protective antigens of Mycoplasma hyopneumoniae delivered as cocktail DNA and/or recombinant protein vaccines in mice
    Austen Y Chen
    Department of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, Queensland, Australia
    Vaccine 26:4372-8. 2008
    ..P97 was not recognized by serum antibodies from commercial bacterin-immunized mice indicating potential lack of expression of this important antigen in inactivated whole-cell vaccines...
  97. ncbi Anthrax vaccines
    A M Friedlander
    U S Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702, USA
    Curr Top Microbiol Immunol 271:33-60. 2002
    ..This chapter will review the recent advances in developing protein, live attenuated, and genetic vaccines against anthrax...
  98. ncbi Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice
    Ai Ninomiya
    Department of Disease Control, Hokkaido University Graduate School of Veterinary Medicine, Sapporo 060 0818, Japan
    Vaccine 20:3123-9. 2002
    ..This approach may prove promising for developing vaccines to induce mucosal CTL responses, and seems to highlight differences between mucosal and non-mucosal immunity...
  99. pmc Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model
    Pablo D Becker
    Virology Laboratory, Ricardo Gutierrez Children s Hospital, Gallo 1330, 1425 Buenos Aires, Argentina
    Infect Immun 75:1778-84. 2007
    ..Thus, rCD is a promising candidate for incorporation in vaccine formulations for use against M. catarrhalis...
  100. ncbi Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults
    David I Bernstein
    Division of Infectious Diseases, Children s Hospital Medical Center, CH 1, 3333 Burnet Ave Rm 1345, Cincinnati, Ohio 45229 3039, USA
    J Infect Dis 185:686-90. 2002
    ..All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected...
  101. ncbi Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus
    C N Wu
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    Vaccine 20:895-904. 2001
    ..We compared the inactivated virus vaccine (10 microg protein/mouse) with subunit vaccines--VP1 DNA vaccine (100 microg/mouse) or recombinant VP1 protein (10 microg/mouse)--in its ability to elicit ..

Research Grants64

  1. Killed But Metabolically Active Leishmania: a novel protozoan vaccine technology
    Noah Craft; Fiscal Year: 2009
    ..Many attempts have been made using killed, attenuated, or subunit vaccines without success...
  2. Screening Complete TB Proteome for Protective Antigens
    Alan Greener; Fiscal Year: 2010
    ..tuberculosis (Mtb) genome, yielding a pool of protective antigens that will immediately enter development as subunit vaccines for tuberculosis...
  3. Development of a Recombinant Tetravalent Dengue Vaccine Based on a Subunit Envelo
    Lynda G Tussey; Fiscal Year: 2013
    ..induction of adaptive immune response, thereby eliminating the need for adjuvants typically used in subunit vaccines. Flagellin contains of four distinct domains (D0, D1, D2, and D3) where D1 contains the TLR5 binding site...
  4. Programming of Protective CD8 T-Cell Memory by Live and Adjuvanted Subunit Vaccin
    Marulasiddappa Suresh; Fiscal Year: 2013
    ..There are only a few adjuvants approved for human use and currently used adjuvanted inactivated/subunit vaccines largely elicit humoral immunity, often require repeated immunization to maintain protective levels of ..
  5. Malaria vaccines modified with TLR agonist adjuvant
    Elizabeth H Nardin; Fiscal Year: 2010
    ..A number of subunit vaccines targeting the pre-erythrocytic and erythrocytic stages of the Plasmodium parasite have recently undergone ..
  6. Generation and Evaluation of KSHV VLPs as Vaccines
    GARY S contact HAYWARD; Fiscal Year: 2010
    ..Based on recent success with prophylactic HPV subunit vaccines to prevent cervical carcinoma, and the demonstration that virus-like particles (VLP) of small viruses such as ..
  7. Adenovirus-vectored RSV vaccine not inhibited by maternal immunity
    JASON GRAHAM GALL; Fiscal Year: 2013
    ..history of failed RSV vaccines, such as formalin-inactivated virus, attenuated viruses, and purified protein subunit vaccines clearly shows the need for a new vaccine design...
  8. Synthetic nanoparticle vaccines for RSV
    THOMAS J POWELL; Fiscal Year: 2012
    ..Efforts to develop recombinant subunit vaccines have met with limited success due to poor immunogenicity and short-lived responses...
  9. "Subunit Vaccines for Brucella Pathogens"
    David W Pascual; Fiscal Year: 2013
    ..Studies in Specific Aim 4 will evaluate various safety parameters for GLP- prepared PotD and PotF subunit vaccines. Thus, these studies will show that subunit vaccines, when appropriately delivered, can protect against ..
  10. Nipah &Hendra Virus Nonhuman Primate Model &Therapeutics Development
    THOMAS WILLIAM GEISBERT; Fiscal Year: 2013
    ..2. Evaluate the protective efficacy of recombinant sG and sF as subunit vaccines for Nipah and Hendra virus in the AGM. 3...
  11. VACCINE INDUCED IMMUNE RESPONSES TO PLASMODIAL ANTIGENS
    JAMES MATTHEW BURNS; Fiscal Year: 2012
    ..Presently, the most viable approach is to immunize with subunit vaccines to induce antibodies that neutralize extracellular merozoites and prevent the invasion of host erythrocytes...
  12. Ehrlichia chaffeensis protective proteins
    David H Walker; Fiscal Year: 2010
    ..by Ehrlichia-specific cross-reactive T cells, and 3) determine the in vivo and ex vivo responses to optimized subunit vaccines delivered by gene and viral vectors and compare them to those associated with E. muris infection...
  13. Epitope shifting and Antibody Maturation during Rotavirus Infection
    Benjamin W Spiller; Fiscal Year: 2012
    ..Second generation vaccines with improved efficacy are sought, and subunit vaccines are an attractive choice...
  14. Virus-Like Particle Vaccines for Pandemic Influenza
    Ted M Ross; Fiscal Year: 2010
    ..VLPs resemble live influenza virus, are immunogenic, and represent an alternative to inactivated or subunit vaccines with the advantage that viral structural antigens are presented in a non-infectious form in the absence of a ..
  15. T cell immunity to Plasmodium sporozoite immunization
    John T Harty; Fiscal Year: 2013
    ..Although a partially protective vaccine (RTS, S) is in phase III trials, subunit vaccines to induce sterilizing liver-stage specific immunity in humans have proven difficult to develop...
  16. Imaging preerythrocytic Plasmodium stages in naive and immune individuals
    Ute Frevert; Fiscal Year: 2010
    ..For example, multivalent subunit vaccines offer numerous advantages including greater safety due to minimized deleterious responses against non-..
  17. Memory CD8 T cell immunity to Plasmodium liver stage infec
    John T Harty; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Much emphasis in the field of subunit vaccines for malaria has been placed on improving the vector systems for antigen-delivery and these empirical ..
  18. An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
    Klaus J Früh; Fiscal Year: 2013
    ..knowlesi sporozoites. Upon completion of this exploratory project, we will thus know whether a TEM-inducing vaccine can improve the level and duration of sterilizing immunity induced by subunit vaccines against malaria parasites.
  19. Depots of persistent influenza antigens support protective CD4 T cell memory
    Dawn M Jelley Gibbs; Fiscal Year: 2010
    ..The results of these studies will provide critical information for the rational design of safe protein subunit vaccines designed to target non-replicating pathogen antigens to beneficial antigen depots for inducing protective ..
  20. Chlamydia trachomatis proteomics
    Guangming Zhong; Fiscal Year: 2013
    ..Understanding the pathogenic mechanisms and developing subunit vaccines have been the major focuses in modern chlamydial research...
  21. HIVRAD: Structural approaches to vaccine development
    Ellis Reinherz; Fiscal Year: 2009
    ..Recent advances now position us to develop subunit vaccines potentially capable of eliciting broad neutralizing antibody (Nab) responses...
  22. Development of stable and rapidly acting adjuvanted vaccines for biodefense
    ROBERT NEWTON BREY; Fiscal Year: 2013
    ..goal of this proposal is to develop processes and specific thermally stable formulations for two biodefense subunit vaccines adsorbed to aluminum adjuvants...
  23. RTB-mediated delivery: Orchestrating antigen trafficking to enhance cell immunity
    Carole L Cramer; Fiscal Year: 2013
    ..b>Subunit vaccines are considered safer than traditional killed or attenuated whole organism vaccines but typically lack the ..
  24. Blocking immune evasion as a novel HSV vaccine approach
    HARVEY MICHAEL FRIEDMAN; Fiscal Year: 2010
    ..In Aim 2 we will compare protection from glycoprotein D (gD-1 or gD-2) subunit vaccines at mucosal and epidermal sites and evaluate the impact of HSV-1 and -2 gC- and gE-mediated immune evasion on ..
  25. Evasion of Antigen Presentation by Rhesus Cytomegalovirus
    Klaus J Früh; Fiscal Year: 2013
    ..specifically the assumptions that live CMV vaccines need to be based on replicating CMV and that single subunit vaccines confer protective T cell responses...
  26. A Sindbis virus-based Vaccine Against RVFV Infection
    Ilya Frolov; Fiscal Year: 2006
    ..This vaccine will combine the efficiency of live attenuated vaccines and safety of the subunit vaccines. In this proposal we will identify i) the optimal strategy for expression of structural proteins of RVFV by ..
  27. Ferric enterobactin acquisition systems in Campylobacter
    Jun Lin; Fiscal Year: 2011
    ..reductase system in Campylobacter;and 3) evaluate the immunogenicity and protective efficacy of CfrA and CfrB subunit vaccines in a chicken model of Campylobacter infection...
  28. Use of a viral mucin-like protein to convert adherent cells to suspension culture
    Angelika Fath-Goodin; Fiscal Year: 2011
    ..The future of human medicine will involve a dramatic increase in development of protein-based drugs and subunit vaccines, whose production will require large-scale propagation of tissue culture cells in suspension culture...
  29. A Novel Cassette System for the Assembly of VLP Vaccines
    MICHAEL N BLACKBURN; Fiscal Year: 2012
    ..The development of recombinant methods for the expression of subunit vaccines has impacted development timelines and costs but subunit vaccines frequently are not as potent as virus ..
  30. DESIGN AND SYNTHESIS OF STRUCTURALLY DEFINED QS-21-BASED SYNTHETIC ADJUVANTS
    Pengfei Wang; Fiscal Year: 2013
    ..It stimulates both Th1 and Th2 type responses, which are extremely important for the development of subunit vaccines against cancers and intracellular pathogens (e.g...
  31. VIBRIO CHOLERAE TCP AND LPS SUBUNIT VACCINE, EPITOPES AN
    William Wade; Fiscal Year: 2004
    ..cholerae colonization factor and a protective antigen. Together, the expertise of these two research groups will provide a unique opportunity to develop and evaluate V: cholerae subunit vaccines using new approaches.
  32. Adjuvants for Agile Vaccine Development
    Philip Felgner; Fiscal Year: 2006
    ..Protein subunit vaccines and DMA vaccines are safer alternatives compared with live attenuated or killed microorganism vaccines...
  33. CD4+ T CELLS RESPONDING TO SALMONELLA INFECTION
    Brad Cookson; Fiscal Year: 2005
    ..The protective Ags identified will be excellent candidates for components of subunit vaccines and markers of cellular immunity in humans.
  34. Smallpox subunit vaccine in the C-PERL expression system
    GEORGE BUCHMAN; Fiscal Year: 2005
    ..Some of the world's leading experts in both poxviruses and subunit vaccines will assist C-PERL in performing the work...
  35. HIV Vaccine Design and Development Team
    PAUL MADDON; Fiscal Year: 2001
    ..At present, subunit vaccines provide the most effective means of inducing robust humoral immune responses by delivering the immunogen in a ..
  36. Human Resistance to Herpes Simplex Virus Infections
    Christine Posavad; Fiscal Year: 2005
    ..The worldwide prevalence of genital HSV-2 continues to increase and the limited success of HSV-2 glycoprotein subunit vaccines underscores the urgency of defining innate resistance and protective immune responses to HSV-2 in humans...
  37. MUCOSAL IMMUNE RESPONSE TO A RECOMBINANT RSV IMMUNOGEN
    SHARON ROBERTS; Fiscal Year: 1999
    ..Currently there are no vaccines available. Previous studies have demonstrated the ability of subunit vaccines based on the HRSV fusion protein, F, to prevent virus replication in the lung...
  38. Trojan Antigens: A Multiple-Epitope Vaccine for Cancer
    Esteban Celis; Fiscal Year: 2007
    ..of numerous T cell epitopes derived from tumor-associated antigens has opened the doors to the development of subunit vaccines for the treatment and prevention of cancer...
  39. VACCINE POTENTIAL OF GONOCOCCAL OMP85
    RALPH JUDD; Fiscal Year: 2001
    ..Recombinant DNA methods make it practical to develop subunit vaccines that focus immune responses to these less abundant, invariant molecules...
  40. EXPRESSION OF SIVmac239 GP120 IN TRANSGENIC MAIZE
    JOSEPH JILKA; Fiscal Year: 2001
    ..The major HIV envelope glycoprotein, gp120, plays a central role in the study of subunit vaccines against HIV, and the related simian virus, SIV...
  41. DEVELOPMENT OF A SYNTHETIC VACCINE TO RETROVIRUSES
    John Elder; Fiscal Year: 1990
    ..We will use synthetic peptides to generate subunit vaccines. We have pinpointed three areas of the envelope gene for more intensive study based on preliminary results...
  42. ADJUVANTICITY OF STEARYL-TYROSINE--SUBUNIT & HIV SYSTEM
    Constantin Bona; Fiscal Year: 1991
    ..a protatype for the development of new generation of vaccines which tend to be poor immunagens such as subunit vaccines. synthetic peptides and idiotype vaccines. 2...
  43. Vaccine discovery for Burkholderia via protection screen
    JEFFREY NORDSTROM; Fiscal Year: 2003
    ..This was accomplished by expression library immunization. Our specific approach to developing one or more subunit vaccines will be to 1) reduce the expression library to its individual protective components, 2) to characterize the ..
  44. Nipah Virus and Hendra Virus Subunit Vaccines
    Christopher Broder; Fiscal Year: 2006
    ..We will evaluate monoclonal and polyclonal antibodies in both reporter-gene membrane fusion assays and in virus-neutralization assays. ..
  45. Adjuvant-free Drug Delivery System
    Michael Sturgess; Fiscal Year: 2004
    ..Although subunit vaccines are safe, inexpensive and elicit specific immune responses, reliable and non-toxic adjuvants are still to be ..
  46. Development of a Plant-based Vaccine aganist HIV
    Michael Horn; Fiscal Year: 2003
    ..inexpensive to produce, plant-based vaccines in corn seed make the ideal delivery system for protein subunit vaccines in areas of the world where a reliable cold chain, needle disposal and top quality medical personnel are ..
  47. ANTI-SENSE OLIGONUCLEOTIDE THERAPY FOR HERPES KERATITIS
    Harry Openshaw; Fiscal Year: 1990
    ..For reasons of safety, subunit vaccines free of HSV DNA are preferable...
  48. DEVELOPMENT OF A CONTROLLED RELEASE HIV VACCINE ADJUVANT
    TREVOR CASTOR; Fiscal Year: 2000
    ..delivery vehicle will have the capability to deliver either a whole inactivated HIV-1 vaccine and1or HIV-1 subunit vaccines. We plan to nanoencapsulate HIV-1 antigens by utilizing an extremely effective nanoencapsulation technique, ..
  49. Development of a Bacteriophage Vaccine Vector System
    STEVE BENDE; Fiscal Year: 2010
    ..with RNA-based vectors and has the potential for dual application as a transient expression system to produce subunit vaccines in vitro and as a vaccine vector directly administrable to humans or animals in vivo...
  50. Transcutaneous Immunization for an Anthrax Vaccine
    Richard Kenney; Fiscal Year: 2003
    ..inactivated viral vaccines, killed bacteria and multivalent high molecular weight (>800,000 Daltons) subunit vaccines. This phase I SBIR will establish the feasibility of topical vaccination with recombinant Protective Antigen ..
  51. Immunogenicity of Synthetic Peptide Malaria Vaccines
    Elizabeth Nardin; Fiscal Year: 2009
    ..Since sporozoites cannot be produced in vitro, efforts have focused on developing subunit vaccines that elicit immune responses comparable to irradiated sporozoites...
  52. Efficacy of soybean-based vaccines using a model antigen
    KENNETH PILLER; Fiscal Year: 2007
    ..will directly address some of the most important challenges that face this technology for developing edible subunit vaccines in soybeans which could be applied to the formulation of novel human gastrointestinal vaccines...
  53. HIV DNA vaccine improvement by nuclear targeting
    Gerd Maul; Fiscal Year: 2003
    ..have unique features that make them advantageous candidates to replace or add to whole virus or recombinant subunit vaccines. In mimicking natural protein expression including secondary modifications, plasmid DNA vaccines can evoke ..
  54. NASALLY-DELIVERED MUCOSAL SUBUNIT VACCINE FOR PLAGUE
    Carole Cramer; Fiscal Year: 2002
    ..and 2) transgenic plant-based bioproduction that addresses issues of safety, scale, and cost of recombinant subunit vaccines. A fusion of the Yersinia pestis protective antigens, F1 and V, appear the most promising for subunit ..
  55. Novel vaccine adjuvants to counter bioterrorist threats
    Nikolai Petrovsky; Fiscal Year: 2009
    ..the physico-chemical characterization, and optimization of inulin-based adjuvants for use in bioterrorism subunit vaccines, determination of the mechanisms of action of inulin-based adjuvants, thereby creating the ability to develop ..
  56. Potentiation Immune Resp vs HIV vacc Modula Innate Resp
    Murali Krishna Kaja; Fiscal Year: 2002
    ..The major differences between live infections and subunit vaccines include high antigenic load and the possibility of low-level antigenic persistence...
  57. Vaccine-enhanced respiratory syncytial virus disease
    FERNANDO POLACK; Fiscal Year: 2004
    ..if either or both RSV protective antigens (fusion (F) and attachment (G) proteins) can be used safely in subunit vaccines or whether disease-enhancement can be avoided using a different method of RSV inactivation or a subunit ..
  58. DEVELOPMENT OF A DETECTIVE HEPATITIS A VIRUS VACCINE
    Gary Van Nest; Fiscal Year: 1990
    ..an alternative to classical killed virus or a attenuated virus vaccine approaches or recombinant DNA derived subunit vaccines, a defective HAV approach will be developed and tested as a HAV vaccine...
  59. ORAL MALARIA VACCINE DEVELOPMENT--P. BERGHEI MODEL
    Robert Brey; Fiscal Year: 1990
    Peptide carrier and recombinant DNA produced Plasmodium falciparum sporozoite subunit vaccines are being tested in clinical trials. These vaccines are designed to induce high titer protective antisporozoite antibodies...
  60. An edible adjuvant expressed in transgenic soybeans
    KENNETH BOST; Fiscal Year: 2005
    ..This is especially true for the development of subunit vaccines that use a single protein isolated from a microbial pathogen in an attempt to protect individuals from viral, ..
  61. Novel Adjuvants/Delivery Systems for Biodefense Vaccines
    NICHOLAS VALIANTE; Fiscal Year: 2005
    ..Lead compounds will be tested as adjuvants for subunit vaccines against category A-C pathogens in combination with microparticle delivery systems developed at Chiron...
  62. CELL BIOLOGY OF HEAT SHOCK PROTEIN MEDIATED IMMUNIZATION
    Hidde Ploegh; Fiscal Year: 2002
    ..Especially activation of CD8+ cytotoxic T cells by exogenously administered subunit vaccines will be a challenge...
  63. HIV-1 ENVELOPE-CD4-CORECEPTOR COMPLEXES AS VACCINES
    Christopher Broder; Fiscal Year: 2001
    ..HIV-1 Env-based subunit vaccines have thus far failed to efficiently generate neutralizing antibodies that are broadly cross-reactive...
  64. IMMUNOGENICITY OF HIV PROTEINS WITH ALPHA-GAL AND TTP
    REBECCA GEFFIN; Fiscal Year: 2001
    DESCRIPTION: (Adapted from Applicant's Abstract) Subunit vaccines are considered safe, but are relatively ineffective in comparison to live attenuated virus vaccines...